Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA VII Commitment Letter Outlines Real-Time Review Expansion, Hiring Goals

Executive Summary

Allergenic extract products, previously excluded, also will become part of the user fee program beginning in FY 2023.

You may also be interested in...



Long-Term Postmarket Studies For Gene Therapies May Need To Be Combined, Standardized

Running multiple product-specific postmarket trials for 15 years or longer would not be cost-effective and one industry stakeholder suggests workstreams eventually could merge.

Emerging Gene Therapy Concern: A Child Joins A Clinical Trial, But Must Be Followed Into Adulthood

The long-term follow-up requirements expected for many gene therapies could raise consent and drop-out issues, which could hinder efforts to track safety and efficacy.

Gene Therapy Sponsors Risk Additional Work With Late-Stage Manufacturing Changes

Commercial scale-up during Phase III trials could create labeling issues and force additional clinical trials, US FDA officials said.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS144832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel